{"id":36111,"date":"2024-11-05T20:49:12","date_gmt":"2024-11-05T17:49:12","guid":{"rendered":"https:\/\/entarabi.com\/?p=36111"},"modified":"2024-11-05T20:49:12","modified_gmt":"2024-11-05T17:49:12","slug":"crescent-enterprises-crossbridge","status":"publish","type":"post","link":"https:\/\/entarabi.com\/en\/2024\/11\/crescent-enterprises-crossbridge\/","title":{"rendered":"Crescent Enterprises Invests $10 Million to Support Cancer Treatment Development with CrossBridge Bio"},"content":{"rendered":"<div class=\"flex max-w-full flex-col flex-grow\">\n<div class=\"min-h-8 text-message flex w-full flex-col items-end gap-2 whitespace-normal break-words [.text-message+&amp;]:mt-5\" dir=\"auto\" data-message-author-role=\"assistant\" data-message-id=\"d8a6f22e-3c5f-4250-98ed-08440d86a083\" data-message-model-slug=\"gpt-4o\">\n<div class=\"flex w-full flex-col gap-1 empty:hidden first:pt-[3px]\">\n<div class=\"markdown prose w-full break-words dark:prose-invert light\">\n<p><a href=\"https:\/\/www.crescententerprises.com\/\" rel=\"nofollow noopener\" target=\"_blank\">Crescent Enterprises<\/a>, the investment arm of Crescent Group, has announced its participation in a $10 million funding round for CrossBridge Bio, a biotechnology company focused on developing innovative treatments. This round was led by TMC Venture, with contributions from Portal Innovations, Alexandria Ventures, and several early-stage investors.<\/p>\n<h3>Supporting Cancer Treatment Development with Dual Payload Technology<\/h3>\n<p>This funding will be used to support the development of CrossBridge Bio\u2019s CBB-120 drug, a potential treatment for solid tumors. The funding will also enhance the company\u2019s dual payload ADC (antibody-drug conjugate) technology, which provides an innovative solution by delivering treatments directly to cancer cells, minimizing unwanted side effects and boosting treatment efficacy.<\/p>\n<p>Additionally, this funding aims to conduct toxicity studies on CBB-120, a preparatory step toward clinical development, according to Dr. Michael Torres, the company&#8217;s CEO.<\/p>\n<h3>Crescent Enterprises and Its Global Investment Expansion<\/h3>\n<p>Crescent Enterprises, which has invested over $500 million in more than 50 companies worldwide, focuses on fast-growing companies in the fields of technology and life sciences, with a special interest in microbiome-based treatments. These technologies aim to improve human health by interacting with beneficial microorganisms in the body.<\/p>\n<p>Read Also: <a href=\"https:\/\/entarabi.com\/en\/2024\/11\/umm-al-quwain-launches-soul-incubator-to-boost-innovation-and-growth\/\">Umm Al Quwain Launches SOUL Incubator to Boost Innovation and Growth<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"mb-2 flex gap-3 empty:hidden -ml-2\">\n<div class=\"items-center justify-start rounded-xl p-1 flex\">\n<div class=\"flex items-center\"><\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Crescent Enterprises, the investment arm of Crescent Group, has announced its participation in a $10 million funding round for CrossBridge Bio, a biotechnology company focused on developing innovative treatments. This round was led by TMC Venture, with contributions from Portal Innovations, Alexandria Ventures, and several early-stage investors. Supporting Cancer Treatment Development with Dual Payload Technology [&hellip;]<\/p>\n","protected":false},"author":37,"featured_media":36107,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"post_subtitle":"","footnotes":""},"categories":[1810],"tags":[6229],"class_list":["post-36111","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fintech","tag-crescent-enterprises"],"_links":{"self":[{"href":"https:\/\/entarabi.com\/en\/wp-json\/wp\/v2\/posts\/36111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/entarabi.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/entarabi.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/entarabi.com\/en\/wp-json\/wp\/v2\/users\/37"}],"replies":[{"embeddable":true,"href":"https:\/\/entarabi.com\/en\/wp-json\/wp\/v2\/comments?post=36111"}],"version-history":[{"count":0,"href":"https:\/\/entarabi.com\/en\/wp-json\/wp\/v2\/posts\/36111\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/entarabi.com\/en\/wp-json\/wp\/v2\/media\/36107"}],"wp:attachment":[{"href":"https:\/\/entarabi.com\/en\/wp-json\/wp\/v2\/media?parent=36111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/entarabi.com\/en\/wp-json\/wp\/v2\/categories?post=36111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/entarabi.com\/en\/wp-json\/wp\/v2\/tags?post=36111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}